Business Wire

LabGenius Appoints Dr. Didier Landais as Chief Operating Officer

Share

LabGenius, the machine learning (ML)-driven protein engineering company, has announced the appointment of Didier Landais Ph.D. as Chief Operating Officer. In this role, Didier will leverage his wealth of experience in business and clinical development to lead the commercialization of LabGenius’ drug discovery platform, EVATM.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210921005586/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

LabGenius Appoints Dr. Didier Landais as Chief Operating Officer (Photo: Business Wire)

“I’m delighted that Didier has joined the team,” said Dr. James Field, Founder and CEO of LabGenius. “Didier is a seasoned operator with 30 years of pharmaceutical industry experience and I’m looking forward to working with him as we rapidly grow the company. It’s a testament to the progress we have made at LabGenius and the exciting opportunities we have ahead of us that we were able to attract someone of Didier’s calibre to join us on our journey.”

Didier joins LabGenius from the pharmaceutical company Servier, where he was The Global Head of Licensing. Under his leadership, Servier signed several notable deals including those with Celsius, Oncodesign and Seal Rock. Prior to Servier, Didier spent over 15 years working for biotechnology and pharmaceutical companies at various stages of development in the US.

Speaking about his appointment, Dr. Didier Landais said: “The team at LabGenius has built an impressive machine learning-driven drug discovery platform with huge potential. I am eager to apply my experience and expertise to support the company’s growth.”

– end –

About LabGenius

LabGenius is a leading ML-driven protein engineering company. The company’s discovery platform, EVATM, integrates several cutting-edge technologies drawn from the fields of computer science, robotic automation and synthetic biology. Headquartered in London, UK, the LabGenius team includes experts in protein engineering, synthetic biology, software engineering, data science and robotic automation.

For more information, please visit www.labgeni.us, or connect on Twitter, Facebook, and LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media enquiries:
Communications Lead
Lucy Shaw
press@labgeni.us

Business development:
Chief Operating Officer
Didier Landais
didier.landais@labgeni.us

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SIGNA Sports United Upsizes PIPE and Principals Agree to Backstop SPAC Business Combination With Yucaipa Acquisition Corporation18.10.2021 09:00:00 CEST | Press release

SIGNA Sports United (“SSU” or the “Company”), the world’s leading sports e-commerce and technology platform, today announced additional PIPE investments and a new redemption backstop agreement related to its proposed business combination agreement with Yucaipa Acquisition Corporation (NYSE: YAC) ("Yucaipa" or "YAC"), a publicly-traded special purpose acquisition company. These additional elements increase deal certainty and ensure the listing of the enlarged pro forma company. Mike Özkan, designated Chairman of the Board of SSU, said, “The upsizing of the PIPE demonstrates the increased interest in SSU’s sports e-commerce and technology platform. The backstop agreement underpins the principal’s commitment to the Company and provides transaction certainty for the strategic combination of the two largest online Bike retailers. The pro forma company will be in a strong position to pursue its mission to digitalize the global sports retail ecosystem with a guaranteed level of liquidity at a

BearingPoint RegTech Becomes Regnology18.10.2021 09:00:00 CEST | Press release

BearingPoint RegTech is now operating under the new name Regnology. The name stands for the company's core business: Regulatory Technology. The change of name is a logical step after BearingPoint Group sold the RegTech business to the private equity firm Nordic Capital end of 2020. Since then, the company is operationally independent. In June 2021, BearingPoint RegTech reached an important milestone by joining forces with Vizor Software, a global leader in RegTech and SupTech based in Dublin. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211018005025/en/ Conor Crowley, CEO Vizor and Head of SupTech at Regnology, and Jürgen Lux, CEO, Regnology (Photo: Regnology) The combined company has a history spanning more than 20 years and is now a leading international provider of innovative regulatory, risk and supervisory technology (RegTech/RiskTech/SupTech) solutions, AEOI and tax reporting, and regulatory reporting services along

NTT: CEOs Say People and the Planet Are Becoming More Important in Business18.10.2021 08:15:00 CEST | Press release

WSJ Intelligence undertook a new international CEO survey for global technology and business solution provider NTT. The survey focuses on the role of business in contributing to societal goals. WSJ Intelligence conducted a survey of 351 CEOs of large corporations representing ten key industries in 15 countries to understand their views on their organization’s role in society, social impact strategies, the stakeholders involved, and how the Covid-19 pandemic has driven these strategies. The research confirms that post-pandemic people and the planet rather than solely profit are becoming increasingly important for organizations of all sizes. While this trend was evident before March 2020, the pandemic brought it to the forefront. The latest research considers, too, how organizations better support employee wellbeing and change management. It uncovers the most valuable tools and tips for social purpose implementation while also analyzing the most significant challenges. Key Findings: 94%

"THE GUNPLA SHOWROOM DUBAI"18.10.2021 08:00:00 CEST | Press release

BANDAI SPIRITS Co., LTD. (President and Chief Executive Officer: Nao Udagawa, Head Office: Minato-ku, Tokyo) will be operating "THE GUNPLA SHOWROOM DUBAI" from late October, 2021 to March 31, 2022, at the Dubai Mall, a shopping mall in Dubai in the city of Dubai in the United Arab Emirates, concurrently with Expo 2020 Dubai that will begin on October 1, 2021. Given the appointment of Gundam as the "PR Ambassador of the Japan Pavilion, Expo 2020 Dubai", we will be promoting Japanese culture and the joy of monodukuri (creating and crafting) to people around the world through Gunpla (Gundam-series plastic models). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211017005004/en/ Display of 1/10 scale standing Gundam statue (Photo: Business Wire) Description of "THE GUNPLA SHOWROOM DUBAI" Exhibit of 1/10 Scale Standing Gundam Statue 1/10 scale standing statue of RX-78-2 (total height: approximately 1,800 mm) will be on exhibit. Lo

Antin Infrastructure Partners to Become Majority Shareholder in Origis Energy, a Leading U.S. Renewable Energy Platform18.10.2021 07:30:00 CEST | Press release

Regulatory News: Antin Infrastructure Partners (Ticker: ANTIN – ISIN: FR0014005AL0), one of the world’s leading infrastructure investment firms, announced today that funds managed by Antin have entered into a definitive agreement to acquire a majority stake in Origis Energy, a major vertically integrated renewable energy platform in the United States, from its CEO & President Guy Vanderhaegen and Global Atlantic Financial Group. The company focuses on developing, building, and operating utility-scale solar and storage assets, as well as distributed generation. Guy Vanderhaegen will continue to lead and to hold a significant stake in the company. Founded in 2008, Origis Energy has a track record of development success across 130 solar and storage projects. Antin will support Origis Energy with additional capital and resources as it builds out its contracted pipeline, which is one of the largest in the U.S. and provides clear visibility into its growth plan over the next several years. T

Nexign Completed Campaign Management Solution for Middle East Telecom Operator Zain Kuwait18.10.2021 07:00:00 CEST | Press release

Nexign (part of ICS Holding), an international provider of business support systems (BSS), has announced that the company completed the Marketing Campaign Management system implementation for Zain Kuwait, one of the leading telecom service providers in the Middle East, in cooperation with the Turkcell Technology, a subsidiary of Turkcell, a converged telecommunication and technology services provider, founded and headquartered in Turkey. The implemented system enables Zain Kuwait to provide targeted offerings to a wide range of its subscribers and boost customer loyalty and retention. Marketing Campaign Management System is a BI-integrated solution for diversified campaigns management during the customer lifecycle. It provides selection rules management to define target segments and communication channels to schedule, execute and track the performance of marketing campaigns. The system enables the company to increase response rates and make sales and marketing initiatives more effectiv

Ipsen Adds Another Program Into Its Pre-Clinical R&D Oncology Pipeline Through an Exclusive Worldwide Collaboration With Accent Therapeutics, Targeting the RNA Modifying Protein, METTL318.10.2021 07:00:00 CEST | Press release

Regulatory News: Disclaimer: Intended for international media and investor audiences only Ipsen (Euronext: IPN; ADR: IPSEY) and Accent Therapeutics (Accent) have signed an exclusive worldwide-collaboration agreement to research, develop, manufacture, and commercialize Accent’s pre-clinical stage METTL3 program. Acute myeloid leukemia (AML) is a difficult to treat cancer of the blood and bone marrow, accounting for a third of all new cases of leukemia in the US each year.1 Globally, the incidence of AML has been increasing year on year across the last 20 years.2 RNA modifying proteins (RMPs) are an emerging target class that control multiple aspects of RNA biology and represent a new approach for the potential treatment of various cancers. METTL3 is an RMP that has been validated pre-clinically as a novel therapeutic target for AML.1,3 This collaboration combines Accent’s expertise in RMP-targeting therapeutics with Ipsen’s capabilities and proven track record in Oncology medicine devel